Actively Recruiting
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Led by Xi'an Jiaotong University · Updated on 2024-05-08
642
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
Sponsors
X
Xi'an Jiaotong University
Lead Sponsor
L
LinkDoc Technology (Beijing) Co. Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer
CONDITIONS
Official Title
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age range from 18 to 80 years old, regardless of gender
- Pancreatic cancer diagnosed by histopathology within 12 weeks after radical surgery
- No neoadjuvant therapy before surgery and no adjuvant therapy after surgery
- ECOG performance status score between 0 and 3
- Voluntary choice of standard chemotherapy or Huaier granules for postoperative adjuvant treatment
- Willingness to participate in research activities, including treatment, follow-up, and data collection
- Signed written informed consent before participation
You will not qualify if you...
- Allergy to Huaier granules or need to avoid or use Huaier granules with caution (for Huaier group)
- Difficulty taking oral medication due to active gastrointestinal bleeding, perforation, or gastric paralysis
- Serious mental illness or other conditions making participation unsuitable
- History of other malignant tumors
- Recent myocardial infarction, cerebral infarction, or other thromboembolic diseases requiring surgery
- Severe infections
- Child Pugh C-grade liver function or renal function 2-5 grades (glomerular filtration rate under 90 ml/min)
- Pregnant, lactating, or planning pregnancy
- Use of other traditional Chinese patent medicines, chemotherapy, or physical therapy with anti-tumor effects within the past 4 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zheng Wang
Xi'an, Shannxi, China, 710065
Actively Recruiting
Research Team
Z
Zheng Wang, PhD
CONTACT
L
Liang Han, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here